Dr Vojo Vukovic joins Synta
This article was originally published in Scrip
Executive Summary
Synta Pharmaceuticals, a US biopharmaceutical company focused on discovering, developing and commercialising small-molecule drugs to treat severe medical conditions, has appointed Dr Vojo Vukovic vice-president of clinical research. He will be the medical lead for the company's most advanced oncology product candidate, elesclomol. Dr Vukovic has more than 15 years' experience in oncology drug development and joins from Pfizer, where he was global medical lead for Sutent and axitinib in a number of cancer indications.
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.